Übersetzung für "Issue a recommendation" in Deutsch

The Commission will issue a Recommendation on Quality Assurance for Statutory Audit.

Following its evaluation, the Commission may issue a recommendation.

The Commission will shortly issue a Recommendation on auditor independence.

The Council would be able to issue a recommendation to such Member States to request financial assistance.

The Expert Group will examine the issue and make a recommendation to the Committee within 120 days of its composition.

The Commission will facilitate a debate on this issue, leading to a Recommendation.

Therefore, the option to issue a ‘Recommendation’ (option in 5.1.2) seems the most appropriate.

If the concerns have not been satisfactorily resolved within a reasonable time, the Commission may issue a recommendation.

However, not everyone knows how to properly issue a letter of recommendation for the nanny.

I believe that this is also the responsibility of the Member States and that perhaps your office should issue a recommendation on this.

Taking into account the potential impact on the HICP, and the consequent uncertainty for users, the Commission considers it necessary to issue a recommendation, regarding the treatment of the reform in the HICP to clarify the existing HICP Regulations.

If the Member State concerned has taken effective action in response to a recommendation under Article 104(7) of the Treaty or a notice issued under Article 104(9) and unexpected adverse economic events with major negative consequences for government finances prevent the correction of the excessive deficit within the time limit set by the Council, it should be possible for the Council to issue a revised recommendation under Article 104(7) or a revised notice under Article 104(9).

Furthermore, if a Community body does not issue a recommendation or does not express an opinion in cases where it is obliged to do so, it can be accused of being passive.

Procedures often end at the stage of critical remarks, which are a means of attempting to prevent the recurrence of cases of maladministration in future, in cases where it would be pointless to issue a recommendation.

In the mean time, and in addition, I would like to ask the Commissioner, following the 2001 Commission recommendation on environmental issues in our new accounts, whether the Commission could issue a similar recommendation on social issues in accounts.

If the Member State concerned has taken effective action in response to a recommendation under Article 104 ( 7 ) or a notice issued under Article 104 ( 9 ) and unexpected adverse economic events with major negative consequences for government finances prevent the correction of the excessive deficit within the time limit set by the Council , it should be possible for the Council to issue a revised recommendation under Article 104 ( 7 ) or a revised notice under Article 104 ( 9 ) .

On 27 April 2015 the European Commission therefore triggered a referral under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data, and requested the PRAC to assess the impact of the above concerns on the benefit-risk balance of ICS containing medicinal products indicated in the treatment of COPD and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked.

On 17 October 2017, Sweden triggered an urgent Union procedure under Article 107i of Directive 2001/83/EC, and requested the PRAC to assess the impact of the above non-adherence to the product information on the benefit-risk balance of hydroxyethyl starch (HES) solutions for infusion and issue a recommendation on whether the marketing authorisations of these products should be maintained, varied, suspended or revoked.

Due to the serious public health impact, Sweden was considering suspending the marketing authorisations for the above mentioned medicinal products, and therefore requested an urgent review of the matter at the European level, and asked the PRAC to assess the impact of the above concerns on the benefit-risk balance of HES solutions for infusion and issue a recommendation on whether the marketing authorisations of these products should be maintained, varied, suspended or revoked.

On 8 March 2016 the BfArM initiated a referral under Article 31 of Directive 2001/83/EC, and asked the CHMP to assess the potential impact of the above findings on the benefit-risk balance of marketing authorisation applications and medicinal products authorised on the basis of relevant trials performed at the inspected site between March 2013-March 2015, and issue a recommendation on whether the marketing authorisations should be maintained, varied, suspended or revoked.

On 08 March 2017 France triggered a procedure under Article 31 of Directive 2001/83/EC, and requested the PRAC to assess the impact on the concerns regarding the effectiveness of the risk minimisation measures on the benefit-risk balance of medicinal products containing substances related to valproate and issue a recommendation on whether the marketing authorisation(s) of these products should be maintained, varied, suspended or revoked.

On 6 July 2016 Paul-Ehrlich-Institut Germany initiated a referral under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data, and requested the PRAC to assess the potential impact of the results of the SIPPET study on the marketing authorisations of relevant FVIII products and to issue a recommendation on whether these should be maintained, varied, suspended or revoked and whether any risk minimisation measures should be implemented.

Having considered the new available evidence from the scientific literature and given the seriousness of the identified safety concerns, the Italian Medicines Agency (AIFA) decided to initiate a review under Article 31 of Council Directive 2001/83/EC on 17 April 2013, referring the matter to the Pharmacovigilance Risk Assessment Committee (PRAC) and requesting the PRAC to issue a recommendation on the benefit-risk of dual RAS blockade therapy through the combined use of ACEinhibitors, ARBs or aliskiren and whether any regulatory measures should be taken on the marketing authorisations of the products involved in this procedure.

On 22 March 2018 Spain therefore triggered a referral under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data, and requested the PRAC to assess the root causes and the impact of the risk of medication errors on the benefit-risk balance of oral formulation of methotrexate and to issue a recommendation on whether the relevant marketing authorisations should be maintained, varied, suspended or revoked.